Literature DB >> 2645933

Do local analgesics injected at the time of third molar removal under general anaesthesia reduce significantly post operative analgesic requirements? A double-blind controlled trial.

J R Tuffin1, D R Cunliffe, S R Shaw.   

Abstract

A prospective, controlled, randomised, double-blind trial suggested that: 1. The use of bupivacaine 0.5% plain and prilocaine 3% with felypressin 0.03 i.u./ml. as peroperative local analgesics reduce postoperative pain scores recorded on the first postoperative morning (P less than 0.05). 2. Bupivacaine 0.5% plain reduces postoperative opiate requirements (P less than 0.025). 3. Patients do not find peroperative bilateral inferior alveolar and lingual nerve blocks with buccal infiltrations significantly unpleasant. Thus peri-operative bupivacaine 0.5% is a valuable adjunct to third molar removal under general anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645933     DOI: 10.1016/0266-4356(89)90123-x

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  4 in total

1.  Summary of the scientific literature for pain and anxiety control in dentistry.

Authors:  L C Hassett
Journal:  Anesth Prog       Date:  1990-07

2.  Effect of Intrapapillary Local Anesthetic on Postoperative Pain Following Dental Treatment Under General Anesthesia in Pediatric Patients.

Authors:  Kelly Lipp; Paul Casamassimo; Ann Griffen; Megann Smiley; Jason Bryant; John Draper; Ashok Kumar
Journal:  Anesth Prog       Date:  2021-12-01

3.  [Preemptive analgesia: a clinical reality or a scientific hypothesis?].

Authors:  M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

4.  The Effectiveness of Ropivacaine and Mepivacaine in the Postoperative Pain after Third Lower Molar Surgery.

Authors:  Vito Crincoli; Gianfranco Favia; Luisa LImongelli; Angela Tempesta; Nicola Brienza
Journal:  Int J Med Sci       Date:  2015-10-16       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.